|
1
|
Matsuzawa Y: The role of fat topology in
the risk of disease. Int J Obes. 32(Suppl 7): S83–S92. 2008.
View Article : Google Scholar
|
|
2
|
Ludwig J, Viggiano TR, McGill DB and Oh
BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a
hitherto unnamed disease. Mayo Clin Proc. 55:434–438.
1980.PubMed/NCBI
|
|
3
|
Powell EE, Cooksley WG, Hanson R, Searle
J, Halliday JW and Powell LW: The natural history of nonalcoholic
steatohepatitis: A follow-up study of forty-two patients for up to
21 years. Hepatology. 11:74–80. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoshiike N and Lwin H: Epidemiological
aspects of obesity and NASH/NAFLD in Japan. Hepatol Res. 33:77–82.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ahrén B: Gut peptides and type 2 diabetes
mellitus treatment. Curr Diab Rep. 3:365–372. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Drucker DJ: Biological actions and
therapeutic potential of the glucagon-like peptides.
Gastroenterology. 122:531–544. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mentlein R, Gallwitz B and Schmidt WE:
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide,
glucagon-like peptide-1(7–36)amide, peptide histidine methionine
and is responsible for their degradation in human serum. Eur J
Biochem. 214:829–835. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deacon CF, Johnsen AH and Holst JJ:
Degradation of glucagon-like peptide-1 by human plasma in vitro
yields an N-terminally truncated peptide that is a major endogenous
metabolite in vivo. J Clin Endocrinol Metab. 80:952–957.
1995.PubMed/NCBI
|
|
9
|
Ahrén B, Landin-Olsson M, Jansson PA,
Svensson M, Holmes D and Schweizer A: Inhibition of dipeptidyl
peptidase-4 reduces glycemia, sustains insulin levels, and reduces
glucagon levels in type 2 diabetes. J Clin Endocrinol Metab.
89:2078–2084. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pratley RE and Salsali A: Inhibition of
DPP-4: A new therapeutic approach for the treatment of type 2
diabetes. Curr Med Res Opin. 23:919–931. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vella A, Bock G, Giesler PD, Burton DB,
Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA and Camilleri
M: Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal
function, meal appearance, and glucose metabolism in type 2
diabetes. Diabetes. 56:1475–1480. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maiztegui B, Borelli MI, Madrid VG, Del
Zotto H, Raschia MA, Francini F, Massa ML, Flores LE, Rebolledo OR
and Gagliardino JJ: Sitagliptin prevents the development of
metabolic and hormonal disturbances, increased β-cell apoptosis and
liver steatosis induced by a fructose-rich diet in normal rats.
Clin Sci (Lond). 120:73–80. 2011. View Article : Google Scholar
|
|
13
|
Yoshida T, Akahoshi F, Sakashita H,
Kitajima H, Nakamura M, Sonda S, Takeuchi M, Tanaka Y, Ueda N,
Sekiguchi S, et al: Discovery and preclinical profile of
teneligliptin
(3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine):
A highly potent, selective, long-lasting and orally active
dipeptidyl peptidase IV inhibitor for the treatment of type 2
diabetes. Bioorg Med Chem. 20:5705–5719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Friedman JM, Leibel RL, Siegel DS, Walsh J
and Bahary N: Molecular mapping of the mouse ob mutation. Genomics.
11:1054–1062. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brunt EM, Janney CG, Di Bisceglie AM,
Neuschwander-Tetri BA and Bacon BR: Nonalcoholic steatohepatitis: A
proposal for grading and staging the histological lesions. Am J
Gastroenterol. 94:2467–2474. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tomas E, Wood JA, Stanojevic V and Habener
JF: Glucagon-like peptide-1 (9–36) amide metabolite inhibits weight
gain and attenuates diabetes and hepatic steatosis in diet-induce
obese.
|
|
17
|
Gao B: Innate immunity and
steatohepatitis: A critical role of another toll (TLR-9).
Gastroenterology. 139:27–30. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dentin R, Girard J and Postic C:
Carbohydrate responsive element binding protein (ChREBP) and sterol
regulatory element binding protein-1c (SREBP-1c): Two key
regulators of glucose metabolism and lipid synthesis in liver.
Biochimie. 87:81–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Foretz M, Guichard C, Ferré P and Foufelle
F: Sterol regulatory element binding protein-1c is a major mediator
of insulin action on the hepatic expression of glucokinase and
lipogenesis-related genes. Proc Natl Acad Sci USA. 96:12737–12742.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Foretz M, Pacot C, Dugail I, Lemarchand P,
Guichard C, Le Lièpvre X, Berthelier-Lubrano C, Spiegelman B, Kim
JB, Ferré P and Foufelle F: ADD1/SREBP-1c is required in the
activation of hepatic lipogenic gene expression by glucose. Mol
Cell Biol. 19:3760–3768. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cohen P and Friedman JM: Leptin and the
control of metabolism: Role for stearoyl-CoA desaturase-1 (SCD-1).
J Nutr. 134:2455S–2463S. 2004.PubMed/NCBI
|
|
22
|
Gastaldelli A, Harrison S, Belfort-Aguiar
R, Hardies J, Balas B, Schenker S and Cusi K: Pioglitazone in the
treatment of NASH: The role of adiponectin. Aliment Pharmacol Ther.
32:769–775. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kersten S, Desvergne B and Wahli W: Roles
of PPARs in health and disease. Nature. 405:421–424. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Knopp RH: Drug treatment of lipid
disorders. N Engl J Med. 341:498–511. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Postic C and Girard J: Contribution of de
novo fatty acid synthesis to hepatic steatosis and insulin
resistance: Lessons from genetically engineered mice. J Clin
Invest. 118:829–838. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Srere PA: The citrate cleavage enzyme. I
Distribution and purification. J Biol Chem. 234:2544–2547.
1959.PubMed/NCBI
|
|
27
|
Abu-Elheiga L, Jayakumar A, Baldini A,
Chirala SS and Wakil SJ: Human acetyl-CoA carboxylase:
Characterization, molecular cloning, and evidence for two isoforms.
Proc Natl Acad Sci USA. 92:4011–4015. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van der Leij FR, Kram AM, Bartelds B,
Roelofsen H, Smid GB, Takens J, Zammit VA and Kuipers JR:
Cytological evidence that the C-terminus of carnitine
palmitoyltransferase I is on the cytosolic face of the
mitochondrial outer membrane. Biochem J. 341:777–784. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park EA, Mynatt RL, Cook GA and Kashfi K:
Insulin regulates enzyme activity, malonyl-CoA sensitivity and mRNA
abundance of hepatic carnitine palmitoyltransferase-I. Biochem J.
310:853–858. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bartlett K and Eaton S: Mitochondrial
beta-oxidation. Eur J Biochem. 271:462–469. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hegarty BD, Turner N, Cooney GJ and
Kraegen EW: Insulin resistance and fuel homeostasis: The role of
AMP-activated protein kinase. Acta Physiol (Oxf). 196:129–145.
2009. View Article : Google Scholar
|
|
32
|
Saltiel AR and Kahn CR: Insulin signalling
and the regulation of glucose and lipid metabolism. Nature.
414:799–806. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kubota N, Kubota T, Itoh S, Kumagai H,
Kozono H, Takamoto I, Mineyama T, Ogata H, Tokuyama K, Ohsugi M, et
al: Dynamic functional relay between insulin receptor substrate 1
and 2 in hepatic insulin signaling during fasting and feeding. Cell
Metab. 8:49–64. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo S, Copps KD, Dong X, Park S, Cheng Z,
Pocai A, Rossetti L, Sajan M, Farese RV and White MF: The Irs1
branch of the insulin signaling cascade plays a dominant role in
hepatic nutrient homeostasis. Mol Cell Biol. 29:5070–5083. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cernea S and Raz I: Therapy in the early
stage: Incretins. Diabetes Care. 34(Suppl 2): S264–S271. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Valera A, Pujol A, Pelegrin M and Bosch F:
Transgenic mice overexpressing phosphoenolpyruvate carboxykinase
develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci
USA. 91:9151–9154. 1994. View Article : Google Scholar : PubMed/NCBI
|
